Search
Powered By HealthLine
Special Offers
Health Tools
 Heart Healthy Diet
 Ideal Body Weight Calculator
 Diet Reviews
 Fitness and Family
 Quiz: Test Your Fitness IQ
 Exercise and Fitness Guide
 Eat Out Smart
 Healthy Cooking
 BMI Calculator
Featured Conditions
 Diet & Exercise
 Stop Smoking
 Food & Fitness
 High Blood Pressure
 Cholesterol
 Heart
Resources
Healthscout News
3D Health Animations
Health Videos
Quizzes & Tools
Health Encyclopedia
Library & Communities
News Archive
Drug Library
Find a Therapist
Enter City or Zip Code:
Powered by Psychology Today



Channels
Home |  Today | Women| Men| Kids| Seniors| Diseases| Addictions| Sex & Relationships| Diet, Fitness, Looks| Alternative Medicine| Drug Checker
 Printer Friendly  Send to a Friend

Two Liver Cancer Treatments Better Than One

Survival time rose with combo therapy for advanced disease, study finds

By Serena Gordon
HealthDay Reporter


Related Encyclopedia
 border=
Adenocarcinoma of the Lung and Brain Metastases
Arteriohepatic Dysplasia
Basal Cell Carcinoma
Bladder Cancer
More...

Related Healthscout Videos
 border=
A Welcome Message from Survivor PJ Hamel
Smother Says "Cut!"
Maryann and Paula
When's the Next Free Mammogram Day? October 17, 2008!!!
More...

Related Animations
 border=
Breast Self-Exam Video
Colon Cancer
Hepatitis
More...

Related Drug Information
 border=
Epogen
Iressa
Procrit
Topamax
More...

Related News Articles
 border=
Team Designs Gold Nanoparticles to Deliver Multiple Drugs
Childhood Leukemia Subtype Resists Treatment
Garlic as a Cancer Fighter? Maybe Not
New Drug May Work Better Against Chemo Side Effects
More...

TUESDAY, April 8 (HealthDay News) -- By combining a special type of chemotherapy (TACE) with another treatment called radiofrequency ablation (RFA), Chinese researchers boosted the survival of people with advanced liver cancer by an average of 13 to 15 months compared to either treatment alone.

"Our study demonstrates that combination therapy with TACE and RFA was an effective and safe treatment that may improve long-term survival for patients with hepatocellular carcinoma larger than three centimeters," said Dr. Bao-Quan Cheng, from the Qilu Hospital and Shandong University School of Medicine in Jinan, China.

Text Continues Below



Results of the study were published in the April 9 issue of the Journal of the American Medical Association.

Hepatocellular carcinoma is responsible for as many as 90 percent of all liver cancers, according to the U.S. National Institutes of Health. Cirrhosis of the liver, often caused by hepatitis B or C or alcoholism, is usually at the root of such cancers. Cirrhosis can make treatment for this type of cancer more difficult, because it damages the liver so much that the liver can't process medications effectively. Only 10 percent to 20 percent of these cancers can be successfully treated with surgery.

For those whose tumors can't be removed with surgery, liver transplantation, chemotherapy and radiofrequency ablation are all options. TACE (transarterial chemoembolization) is a special type of chemotherapy that delivers chemotherapy drugs directly to the blood vessels feeding the tumor. Radiofrequency ablation uses electrodes to produce heat and destroy cancerous tissue.

The most commonly used treatment in the United States for advanced liver cancer is transplantation, according to Dr. Milan Kinkhabwala, chief of abdominal transplantation at Montefiore Medical Center in New York City. "If the tumor can't be resected [surgically removed], liver transplantation is the definitive treatment," he said, adding that transplantation might not be as available in China as it is in the United States.

Page:  1 | 2 | Next >>

Copyright © 2008 ScoutNews, LLC. All rights reserved.
Last updated 4/8/2008

Related Links
 border=
From Healthscout's partner site on cholesterol, CholesterolNetwork.com
VIDEO: Open Arteries with a Cancer Drug
ONLINE TEST: Take our Home Body Fat Test!
QUIZ: Recommended Daily Calories and Fat





SOURCES: Bao-Quan Cheng, M.D., Ph.D., Qilu Hospital, Shandong University School of Medicine, Jinan, China; Milan Kinkhabwala, M.D., chief, abdominal transplantation, Montefiore Medical Center, New York City; April 9, 2008, Journal of the American Medical Association


We comply with the HONcode standard for trustworthy health
information:
verify here.
About The HealthScout Network Contact Us
Copyright © 2001-2009. The HealthCentralNetwork, Inc. All rights reserved.
Privacy Policy  Terms of Service